Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.43 |
| ▸ | MDM4 | O15151 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 3/20 | 0.36 |
| ▸ | CTSB | P07858 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7238575 | 1.00 | MAPT (0.43) | MAPTLMNAMDM2MDM4ALDH1A1 | |
| SCHEMBL26294007 | 0.80 | MAPT (0.45) | MAPTLMNAMDM2MDM4ALDH1A1 | |
| SCHEMBL27429610 | 0.75 | LTA4H (0.54) | — | |
| SCHEMBL30511413 | 0.73 | MAPT (0.42) | MAPTLMNAMDM2MDM4CTSL | |
| SCHEMBL15756462 | 0.72 | MAPT (0.50) | MAPTLMNAMDM2MDM4ALDH1A1 | |
| SCHEMBL15756460 | 0.72 | MAPT (0.50) | MAPTLMNAMDM2MDM4ALDH1A1 | |
| SCHEMBL15764578 | 0.72 | MAPT (0.50) | MAPTLMNAMDM2MDM4ALDH1A1 | |
| SCHEMBL21690121 | 0.72 | LTA4H (0.56) | — | |
| SCHEMBL28685286 | 0.72 | LTA4H (0.56) | — | |
| SCHEMBL7850584 | 0.72 | LTA4H (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6514997-B2 | Block the activity of picornaviral 3C protease | AGOURON PHARMACEUTICALS, INC. | 2003-02-04 | — | — | US | disclosed |
| EP-1252145-A1 | ANTIPICORNAVIRAL COMPOUNDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20010047006-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. | 2001-11-29 | — | — | US | disclosed |
| WO-2001040189-A1 | ANTIPICORNAVIRAL COMPOUNDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND MATERIALS FOR THEIR SYNTHESIS | AGOURON PHARMACEUTICALS, INC. (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047006-A1 | Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis | RNASE1, SERPINB1, RNASEH1 | MAPT 2641/4885LMNA 593/4885MDM2 3141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.